Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)

[1]  S. Culine,et al.  Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? , 2007, British Journal of Cancer.

[2]  N. Pavlidis,et al.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray. , 2007, European journal of cancer.

[3]  A. Arcaro,et al.  Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? , 2007, Cancer treatment reviews.

[4]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[5]  N. Pavlidis,et al.  Cancer of unknown primary site: missing primary or missing biology? , 2007, The oncologist.

[6]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Pavlidis,et al.  The Biology of Unknown Primary Tumors: The Little We Know, the Importance of Learning More , 2006 .

[8]  K. Fizazi.  Carcinoma of an Unknown Primary Site , 2006 .

[9]  A. Metspalu,et al.  Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. , 2005, Clinical chemistry.

[10]  David E. Misek,et al.  Analysis of Tumor-Host Interactions by Gene Expression Profiling of Lung Adenocarcinoma Xenografts Identifies Genes Involved in Tumor Formation , 2005, Molecular Cancer Research.

[11]  P. Petrow,et al.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Culine,et al.  Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. la Vecchia,et al.  Epidemiology of unknown primary tumours. , 2002, European journal of cancer.

[14]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[15]  C. Staedel,et al.  Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell line , 2002, International journal of cancer.

[16]  N. Pavlidis,et al.  Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kashiwazaki,et al.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. , 1999, Cancer research.

[18]  A. Horwich,et al.  Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin‐Embedded Samples , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[19]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[20]  Kevin R Coombes,et al.  Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. , 2007, Cancer research.

[21]  A. Griffioen,et al.  Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. , 2004, Anticancer research.

[22]  A. Papadopoulou,et al.  Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. , 2003, Neoplasia.

[23]  J. Coebergh,et al.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.

[24]  J. Abbruzzese,et al.  p53 gene mutation spectrum in human unknown primary tumors. , 1993, Anticancer research.

[25]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[26]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.